IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ITP IT Tech Packaging Inc

Closed Mourning Day 01-08 16:00:00 EST

0.4500

+0.0288

+6.84%

盘后0.4151

-0.0349-7.76%

19:53 EST

High0.4500	Low0.3695	Vol472.40K
Open0.3695	D1 Closing0.4212	Amplitude19.11%
Mkt Cap4.53M	Tradable Cap4.29M	Total Shares10.07M
T/O191.58K	T/O Rate4.96%	Tradable Shares9.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ITP","market":"US","secType":"STK","nameCN":"IT Tech Packaging Inc","latestPrice":0.45,"timestamp":1736370000000,"preClose":0.4212,"halted":0,"volume":472404,"hourTrading":{"tag":"盘后","latestPrice":0.4151,"preClose":0.45,"latestTime":"19:53 EST","volume":80831,"amount":33457.225829,"timestamp":1736384019161},"delay":0,"floatShares":9524204,"shares":10065920,"eps":-0.98,"marketStatus":"Closed Mourning Day","change":0.0288,"latestTime":"01-08 16:00:00 EST","open":0.3695,"high":0.45,"low":0.3695,"amount":191583.64060968,"amplitude":0.191121,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.98,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1736499600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"AMEX","adjPreClose":0.4212,"preHourTrading":{"tag":"盘前","latestPrice":0.4219,"preClose":0.4212,"latestTime":"09:28 EST","volume":6817,"amount":2991.19645879,"timestamp":1736346532151},"postHourTrading":{"tag":"盘后","latestPrice":0.4151,"preClose":0.45,"latestTime":"19:53 EST","volume":80831,"amount":33457.225829,"timestamp":1736384019161},"volumeRatio":0.01566986938778967,"impliedVol":1.2507,"impliedVolPercentile":0.8929},"requestUrl":"/m/hq/s/ITP/wiki","defaultTab":"wiki","newsList":[{"id":"2501751734","title":"Kissei Pharma Partners with Tai Tien for Tavalisse Drug Development, Commercialization in Taiwan","url":"https://stock-news.laohu8.com/highlight/detail?id=2501751734","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501751734?lang=en_us&edition=fundamental","pubTime":"2025-01-08 07:08","pubTimestamp":1736291322,"startTime":"0","endTime":"0","summary":"Kissei Pharmaceutical  has signed a sub-licensing deal with Tai Tien Pharmaceuticals for the development and commercialization of Tavalisse  in Taiwan, according to a Tuesday filing on the Tokyo Stock Exchange.Tai Tien will receive commercialization rights, while Kissei will supply the product and receive upfront and milestone payments.The oral SYK inhibitor, approved in multiple regions, treats chronic idiopathic thrombocytopenic purpura .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4199","ITP"],"gpt_icon":0},{"id":"2501206311","title":"Bionano Announces Publication Showing that OGM Identifies Variant that Indicates Use of Proven Therapy in Acute Promyelocytic Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2501206311","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501206311?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:00","pubTimestamp":1736254800,"startTime":"0","endTime":"0","summary":"A case study published by researchers at Johns Hopkins University showed that optical genome mapping (OGM) detected a structural variant that was missed by karyotyping and non-informative by FISH, whi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/07/3005378/0/en/Bionano-Announces-Publication-Showing-that-OGM-Identifies-Variant-that-Indicates-Use-of-Proven-Therapy-in-Acute-Promyelocytic-Leukemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4197","ITP","BK4588","BK4199","ATRA","ATO","BK4585","BK4139"],"gpt_icon":0},{"id":"2501606342","title":"Press Release: Bionano Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2501606342","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501606342?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:30","pubTimestamp":1736199000,"startTime":"0","endTime":"0","summary":"Bionano Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules. SAN DIEGO, Jan. 06, 2025  -- Bionano Genomics, Inc.  today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 39,682,540 shares of its common stock  and warrants to purchase up to an aggregate of 39,682,540 shares of common stock , at a combined offering price of $0.252 per share of common stock  and accompanying Warrant. The Warrants have an exercise price of $0.252 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants . The Warrants will expire on the five-year anniversary of the Stockholder Approval.H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.This press release shall not constitute an offer to sell or a solicitation of an o","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","IE00B3QW5Z07.USD",".IXIC","TSYW.SI","ITP","SQQQ","LU2095319765.USD","IE00BGHQF748.EUR","NQmain","BK4588","USJW.SI","LU2210150020.SGD","QID","BK4121","PSQ","MNQmain","TQQQ","BK4585","QLD","IE00B64PRP62.GBP","NVIW.SI","NDAQ","USAW.SI","LU2210149790.SGD","BNGO","BK4575","IE00BKPKM429.USD","BK4112"],"gpt_icon":1},{"id":"2501718250","title":"Interparfums' Frédéric Garcia-Pelayo Leaves Effective April 17 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501718250","media":"T-Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501718250?lang=en_us&edition=fundamental","pubTime":"2025-01-07 01:24","pubTimestamp":1736184289,"startTime":"0","endTime":"0","summary":"Interparfums SA :Interparfums' Frédéric Garcia-Pelayo, Managing Director Of International Affairs For Montblanc, Coach, Lacoste And Van Cleef & Arpels Brand, Leaves.Frédéric Garcia-Pelayo Replaced By Daphné Benacin, Currently Regional Export Director.Leave Effective April 17 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199"],"gpt_icon":0},{"id":"2501423190","title":"CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2501423190","media":"ACCESSWIRE","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501423190?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168400,"startTime":"0","endTime":"0","summary":"BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the first patient has been dosed in the Phase 1/2 trial to evaluate the safety and tolerability of CID-103 in adult patients with chronic Immune Thrombocytopenia  in China.\"Dosing the first patient in our phase 1/2 study marks a significant milestone for both CID-103 program and chronic ITP patients who have limited treatment options,\" said Dr. Wei-Wu He, Chairman and CEO of CASI, \"The rapid execution underscores our commitment to accelerating clinical development. This phase 1/2 study is designed to deliver important safety and dose-response data, providing valuable insights to guide the future development of CID-103 for additional autoimmune indications with significant unmet medical needs.\". CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody recogniz","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/casi-announces-first-patient-dosed-130000573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CID","ITP","CASI","BK4199","BK4139"],"gpt_icon":0},{"id":"2500860123","title":"Press Release: Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2500860123","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500860123?lang=en_us&edition=fundamental","pubTime":"2025-01-04 03:34","pubTimestamp":1735932840,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan. 03, 2025  -- Bionano Genomics, Inc.  today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 39,682,540 shares of its common stock  and warrants to purchase up to an aggregate of 39,682,540 shares of common stock , at a combined offering price of $0.252 per share of common stock  and accompanying Warrant in a registered direct offering priced at-the-market under Nasdaq rules. The Warrants will have an exercise price of $0.252 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants  for a period of five years thereafter. The closing of the offering is expected to occur on or about January 6, 2024, subject to the satisfaction of customary closing conditions.H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSQ","IE00BGHQF748.EUR","NQmain","IE00BKPKM429.USD","BK4585","TSYW.SI",".IXIC","SQQQ","IE00B3QW5Z07.USD","BNGO","NVIW.SI","MNQmain","BK4121","BK4575","USJW.SI","QLD","QID","BK4199","BK4112","USAW.SI","IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","ITP","TQQQ","BK4588","LU2210150020.SGD","LU2210149790.SGD"],"gpt_icon":1},{"id":"2500264208","title":"Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2500264208","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500264208?lang=en_us&edition=fundamental","pubTime":"2025-01-01 04:26","pubTimestamp":1735676760,"startTime":"0","endTime":"0","summary":"Provides financial flexibility by reducing near-term debt maturities, deferring principal redemption payment, and reducing near-term cash needsSAN DIEGO, Dec.  31, 2024  (GLOBE NEWSWIRE) -- Bionano Ge","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/31/3003198/0/en/Bionano-Announces-Amendment-to-Senior-Secured-Convertible-Debentures-in-Debt-Restructuring-that-Improves-Cash-Runway.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP"],"gpt_icon":0},{"id":"2495193946","title":"Amex Halt  Add Info Lst 0.820000","url":"https://stock-news.laohu8.com/highlight/detail?id=2495193946","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495193946?lang=en_us&edition=fundamental","pubTime":"2024-12-31 23:15","pubTimestamp":1735658118,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241231:nAQN2JW9FO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ITP","BK4199"],"gpt_icon":0},{"id":"2495227613","title":"Amex Halt  Add Info Lst 0.830000","url":"https://stock-news.laohu8.com/highlight/detail?id=2495227613","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495227613?lang=en_us&edition=fundamental","pubTime":"2024-12-31 22:32","pubTimestamp":1735655539,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241231:nAQN2JW9FQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ITP","BK4199"],"gpt_icon":0},{"id":"2493750333","title":"Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2493750333","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493750333?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:30","pubTimestamp":1734960600,"startTime":"0","endTime":"0","summary":"In the largest study to date of bone and soft tissue tumors, OGM detected 100% of the variants found by multiple standard techniques, including karyotyping, fluorescent in-situ hybridization (FISH) & ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/23/3001237/0/en/Bionano-Announces-Publication-from-Johns-Hopkins-School-of-Medicine-Showing-that-OGM-Outperformed-Multiple-Cytogenetic-Assays-in-a-Study-of-Bone-and-Soft-Tissue-Tumor-Analysis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4179","NGS","BK4199","ITP"],"gpt_icon":0},{"id":"2492127283","title":"Bionano Announces the Publication of Stockholder Letter Regarding Support for Proxy Proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2492127283","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492127283?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":"Dear Fellow Stockholders: I am writing to highlight the importance of the proposals described in our Definitive Proxy Statement, filed with the SEC on December 5, 2024 for a special meeting of stockholders to be held on January 15, 2025, and to ask that you support them. In particular, I am asking you to vote FOR proposal 2, the reverse stock split proposal. While a reverse stock split is not something Bionano’s Board of Directors or management desire to undertake, we do believe it is necessary because: A reverse stock split would support ongoing compliance with Nasdaq listing requirements. As a listed company on the Nasdaq Capital Market, one of the continued listing requirements for our common stock is a minimum bid price of at least $1.00 per share. Since our stock, which closed at $0.21 yesterday, has traded below $1.00 since the end of May 2024, we are at risk of having our stock delisted. A Nasda","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/19/2999794/0/en/Bionano-Announces-the-Publication-of-Stockholder-Letter-Regarding-Support-for-Proxy-Proposal.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BNGO","MNQmain","BK4199","BK4575","PSQ","ITP","TQQQ","NVIW.SI","TSYW.SI","QLD",".IXIC","QID","SQQQ","NQmain","USAW.SI","USJW.SI"],"gpt_icon":1},{"id":"2490802153","title":"Sobi Announces FDA Acceptance of New Drug Application for Avatrombopag (DOPTELET®) for the Treatment of Pediatric Immune Thrombocytopenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2490802153","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490802153?lang=en_us&edition=fundamental","pubTime":"2024-12-12 19:59","pubTimestamp":1734004740,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Dec. 12, 2024  -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB  , today announced that the U.S. Food and Drug Administration  has accepted its supplemental New Drug Application  for avatrombopag  for the treatment of thrombocytopenia in pediatric patients one year and older with persistent or chronic immune thrombocytopenia  who have had an insufficient response to a prior therapy.The FDA assigned a Prescription Drug User Fee Act  target action date ofJuly 24, 2025.“These application acceptances for avatrombopag brings us one step closer to much-needed, additional treatment options for adolescents and children with persistent and chronic ITP,” said Jamie Freedman, MD, PhD, Chief Medical Officer, Sobi North America. “Now, there’s an opportunity to address an unmet need in our pediatric population, with the added bonus of an additional formulation, an oral suspension option that may be more suitable for some patients.”About DOPTELET DOPT","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/x7YFyGf5t1TpmaBcFH5NNQ--~B/aD0yNzQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c87171b9fa161c1111e7d2f803fd59a9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/x7YFyGf5t1TpmaBcFH5NNQ--~B/aD0yNzQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c87171b9fa161c1111e7d2f803fd59a9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sobi-announces-fda-acceptance-drug-115900636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ITP","BK4199","BK4139","SWOBY","BIOVF"],"gpt_icon":0},{"id":"2490018213","title":"Bionano Announces Presentations at the American Society of Hematology (ASH) Annual Meeting that Underscore OGM Utility Across Blood Cancer Research and Cell & Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2490018213","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490018213?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:00","pubTimestamp":1733835600,"startTime":"0","endTime":"0","summary":"Thirteen scientific posters feature results from OGM applications in myeloid cancers, acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), lymphoma, and other hematological malignancy ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/10/2994491/0/en/Bionano-Announces-Presentations-at-the-American-Society-of-Hematology-ASH-Annual-Meeting-that-Underscore-OGM-Utility-Across-Blood-Cancer-Research-and-Cell-Gene-Therapy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ASH","BK4117","LU2355687059.USD","BK4533","LU1699723380.USD","BK4585","BK4588","LU2463526074.USD","BK4107","ALL","ITP","LU0985320562.USD","AFG","LU1571399168.USD","BK4109"],"gpt_icon":0},{"id":"2489060227","title":"Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP","url":"https://stock-news.laohu8.com/highlight/detail?id=2489060227","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489060227?lang=en_us&edition=fundamental","pubTime":"2024-12-08 00:30","pubTimestamp":1733589000,"startTime":"0","endTime":"0","summary":"ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP. Pivotal phase 3 data show rapid and durable platelet response, reduced bleeding and need for rescue response, and improved physical fatigue and quality of life measures in patients with persistent or chronic ITP. Rilzabrutinib is currently under regulatory review in the US and the EU. In the pivotal LUNA 3 study, adult patients with persistent or chronic ITP and severely low platelet counts  received oral rilzabrutinib 400 mg twice a day  or placebo  for up to 24 weeks followed by 28 weeks of open-label period and demonstrated the following results:. Platelet response  was achieved in 65%  of patients receiving rilzabrutinib compared to 33%  of patients on placebo. The primary endpoint of durable platelet response, defined as the proportion of participants able to achieve platelet counts at or above 50,000/μL for at least 8","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OPTreMFV4QxkZ_hb1FVJzw--~B/aD0xNjc7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9e521264632e7a9a44e3450108999128","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OPTreMFV4QxkZ_hb1FVJzw--~B/aD0xNjc7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9e521264632e7a9a44e3450108999128"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/press-release-ash-rilzabrutinib-demonstrated-163000596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0048573645.USD","SG9999001135.SGD","SG9999014492.USD","SG9999002620.SGD","SG9999006266.SGD","BK4554","SG9999013486.USD","LU2125910500.SGD","SG9999013478.USD","IE00BFXG1179.USD","ITP","SG9999005177.SGD","SG9999013460.SGD","LU0532188223.SGD","SG9999002406.SGD","BK4581","LU0251143029.SGD","BK4503","IE0034224299.USD","ASH","BK4551","LU0210637038.USD","SNY","SG9999002414.USD","SG9999002679.SGD","SGXZ58947870.SGD","LU0261945553.USD","BK4007","BK4085","LU0737861269.HKD","SG9999014484.SGD","BK4585","BK4109","BK4566","BK4535","BK4588","LU2045819591.USD","LU2463526074.USD","SG9999002604.SGD","SG9999004360.SGD","BK4548","BK4199"],"gpt_icon":1},{"id":"2484612923","title":"Brady, Aecom And 3 Stocks To Watch Heading Into Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2484612923","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484612923?lang=en_us&edition=fundamental","pubTime":"2024-11-18 15:58","pubTimestamp":1731916697,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/42029825/brady-aecom-and-3-stocks-to-watch-heading-into-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACM","BK4142","BK4595","LU0572944931.SGD","LU0370786039.SGD","LU0143863784.USD","LU1868837565.USD","LU1961090484.USD","BTDR","LU0737861772.HKD","LU0828237510.HKD","BK4588","IE00B3M56506.USD","LU0650527681.SGD","LU1794554557.SGD","LU2065732104.USD","BK4023","LU0048580855.USD","LU0348825331.USD","TCOM","BK4516","IE00B5MMRT66.SGD","BRC","LU2308191902.HKD","BK4585","LU0327786744.USD","LU0593848301.USD","IE00B543WZ88.USD","LU0315179316.USD","LU0228659784.USD","BK4534","ITP","LU0049853897.USD","LU1720050803.USD","LU1868837722.USD","LU0359201612.USD","BK4531","LU0359202008.SGD","LU0561508036.HKD","IE00BPRC5H50.USD","BK4526","IE00B0JY6N72.USD","LU0594300419.USD","LU1023057109.AUD","BK4129","LU1868838027.USD","LU2152927971.USD","LU0329678337.USD","BK4199","LU0143863198.USD"],"gpt_icon":0},{"id":"2483315965","title":"IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2483315965","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483315965?lang=en_us&edition=fundamental","pubTime":"2024-11-16 06:30","pubTimestamp":1731709808,"startTime":"0","endTime":"0","summary":"IT Tech Packaging (AMEX:ITP) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year.  The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/42020756/it-tech-packaging-q3-eps-0-20-same-yoy-sales-25-08m-up-from-15-77m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP"],"gpt_icon":0},{"id":"2483753907","title":"IT Tech Packaging Q3 Income From Operations USD -1.46 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483753907","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483753907?lang=en_us&edition=fundamental","pubTime":"2024-11-16 06:27","pubTimestamp":1731709674,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nPLXA07EF5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4199","ITP"],"gpt_icon":0},{"id":"2483539006","title":"IT Tech Packaging Inc. Announces Third Quarter 2024 Unaudited Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483539006","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483539006?lang=en_us&edition=fundamental","pubTime":"2024-11-16 06:27","pubTimestamp":1731709673,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nTUA10JH0J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ITP","BK4199"],"gpt_icon":0},{"id":"2483531009","title":"IT Tech Packaging Inc. Announces third Quarter 2024 Unaudited Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483531009","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483531009?lang=en_us&edition=fundamental","pubTime":"2024-11-16 06:27","pubTimestamp":1731709620,"startTime":"0","endTime":"0","summary":"Revenue increased by 59.03% to approximately $25.08 million as compared to the same period of last year. This was mainly due to the increase of sales volume of corrugating medium paper , partially offset by the decrease in average selling prices  of CMP.Gross profit increased by 1351.37% to approximately $1.92 million as compared to the same period of last year. Total gross profit margin increased by 8.61 percentage point to 7.64%.Loss from operations was approximately $1.46 million, compared to approximately $2.48 million for the same period of last year.Net loss was approximately $1.97 million, or loss per share of $0.20, compared to net loss of approximately $1.98 million, or loss per share of $0.20, for the same period of last year.Earnings before interest, taxes, depreciation and amortization  was approximately $2.03 million, compared to$1.69 million for the same period of last year.The following table summarizes revenue, volume and ASP by product for the third quarter of 2024 and","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/G0LH6IQ4dxTrcu5xCOxLkA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/db5026683ceaabb4aea7e383e06fc3f7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/G0LH6IQ4dxTrcu5xCOxLkA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/db5026683ceaabb4aea7e383e06fc3f7"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tech-packaging-inc-announces-third-222700306.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tech-packaging-inc-announces-third-222700306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4199","ITP"],"gpt_icon":0},{"id":"2483373349","title":"CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483373349","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483373349?lang=en_us&edition=fundamental","pubTime":"2024-11-15 21:00","pubTimestamp":1731675600,"startTime":"0","endTime":"0","summary":"BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc.  , a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended September 30, 2024.Dr. Wei-Wu He, Chairman and CEO of CASI, said \"The third quarter of 2024 marks a period of substantial progress for CASI as we continue to refine our company's strategic focus on the development for organ transplant rejection and autoimmune diseases. We just announced the Center for Drug Evaluation  of China's National Medical Products Administration  has approved our Clinical Trial Application  for a phase 1/2 study of CID-103 in patients with chronic Immune Thrombocytopenia  in China. This China study is part of the global study that was approved by the US FDA in May. Furthermore, we are making steady progress towards filing the Investigational New Dru","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/casi-pharmaceuticals-announces-third-quarter-130000842.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CASI","BK4585","CTA","BK4588","BK4139","CDE","BK4006","BK4017","BK4199","ITP","AMR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.itpackaging.cn","stockEarnings":[{"period":"1week","weight":-0.2517},{"period":"1month","weight":0.9149},{"period":"3month","weight":0.3838},{"period":"6month","weight":0.8939},{"period":"1year","weight":0.5254},{"period":"ytd","weight":-0.2517}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0251},{"period":"3month","weight":0.0232},{"period":"6month","weight":0.0527},{"period":"1year","weight":0.244},{"period":"ytd","weight":0.0058}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"IT Tech Packaging, Inc., together with its subsidiaries, engages in the production and distribution of paper products in the People's Republic of China. The company operates through three segments: Dongfang Paper, Tengsheng Paper, and Baoding Shengde. It offers corrugating medium papers to companies making corrugating cardboards; and offset printing papers to printing companies. The company also provides tissue paper products, including toilet papers, boxed and soft-packed tissues, handkerchief tissues, and paper napkins, as well as bathroom and kitchen paper towels under the Dongfang Paper brand. In addition, it produces and sells non-medical single-use face masks, and medical face masks. The company was formerly known as Orient Paper, Inc. and changed its name to IT Tech Packaging, Inc. in August 2018. The company is headquartered in Baoding, the People's' Republic of China.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.008581},{"month":2,"riseRate":0.333333,"avgChangeRate":0.001377},{"month":3,"riseRate":0.2,"avgChangeRate":-0.003643},{"month":4,"riseRate":0.333333,"avgChangeRate":0.044398},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.107909},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.040993},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.051814},{"month":8,"riseRate":0.133333,"avgChangeRate":-0.080956},{"month":9,"riseRate":0.4,"avgChangeRate":-0.016928},{"month":10,"riseRate":0.4,"avgChangeRate":0.047355},{"month":11,"riseRate":0.4,"avgChangeRate":0.109469},{"month":12,"riseRate":0.133333,"avgChangeRate":0.004344}],"exchange":"AMEX","name":"IT Tech Packaging Inc","nameEN":"IT Tech Packaging Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest IT Tech Packaging Inc(ITP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"IT Tech Packaging Inc,ITP,IT Tech Packaging Inc股票,IT Tech Packaging Inc股票老虎,IT Tech Packaging Inc股票老虎国际,IT Tech Packaging Inc行情,IT Tech Packaging Inc股票行情,IT Tech Packaging Inc股价,IT Tech Packaging Inc股市,IT Tech Packaging Inc股票价格,IT Tech Packaging Inc股票交易,IT Tech Packaging Inc股票购买,IT Tech Packaging Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest IT Tech Packaging Inc(ITP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction